- Home
- GENK vs SLGL Comparison
GENK vs SLGL Comparison
Compare GENK & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- SLGL
- Stock Information
- Founded
- GENK 2011
- SLGL 1997
- Country
- GENK United States
- SLGL Israel
- Employees
- GENK N/A
- SLGL N/A
- Industry
- GENK Restaurants
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- SLGL Health Care
- Exchange
- GENK Nasdaq
- SLGL Nasdaq
- Market Cap
- GENK 16.3M
- SLGL 69.1M
- IPO Year
- GENK 2023
- SLGL 2018
- Fundamental
- Price
- GENK $3.07
- SLGL $23.98
- Analyst Decision
- GENK Strong Buy
- SLGL
- Analyst Count
- GENK 2
- SLGL 0
- Target Price
- GENK $7.00
- SLGL N/A
- AVG Volume (30 Days)
- GENK 47.0K
- SLGL 33.1K
- Earning Date
- GENK 11-11-2025
- SLGL 11-14-2025
- Dividend Yield
- GENK 3.77%
- SLGL N/A
- EPS Growth
- GENK N/A
- SLGL N/A
- EPS
- GENK N/A
- SLGL N/A
- Revenue
- GENK $216,137,000.00
- SLGL $23,931,000.00
- Revenue This Year
- GENK $12.35
- SLGL N/A
- Revenue Next Year
- GENK $14.62
- SLGL $31.17
- P/E Ratio
- GENK N/A
- SLGL N/A
- Revenue Growth
- GENK 10.67
- SLGL 264.86
- 52 Week Low
- GENK $3.05
- SLGL $4.01
- 52 Week High
- GENK $10.33
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- GENK 36.81
- SLGL 58.56
- Support Level
- GENK $3.11
- SLGL $23.13
- Resistance Level
- GENK $3.39
- SLGL $24.85
- Average True Range (ATR)
- GENK 0.15
- SLGL 2.36
- MACD
- GENK 0.02
- SLGL -0.43
- Stochastic Oscillator
- GENK 5.13
- SLGL 39.19
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.